** Shares of biotech firm ImmunoPrecise Antibodies IPA.O rise ~42% to 69 cents
** IPA says it has developed a new class of GLP-1 therapies using AI to improve diabetes treatment
** IPA's proprietary tech, called LENSai, uses patterns in biological data to create novel genetic sequences for GLP-1-like constructs
** Co says it is investigating transdermal delivery of these therapies as a non-invasive alternative to injections
** More than 300 mln shares traded, 708x times their 25-day moving avg
** IPA fell ~76% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.